Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
2.63 ^USD	-3.31%		+6.05%	-71.26%

05-15	Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Dermata Therapeutics, LLC announced that it expects to receive $6.906244 million in funding

January 31, 2015

Dermata Therapeutics, LLC announced that it will receive funding on January 1, 2016. The company will issue membership units in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	01-05	MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	01-05	MT
Top Premarket Gainers	01-05	MT
North American Morning Briefing : Bond Yields Rise Again as Jobs Data Loom	01-05	DJ
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne	12-20	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16	MT
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million	11-16	MT
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols	11-16	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne	23-06-27	CI
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis	23-06-08	CI
Dermata Therapeutics Completes $1.8 Million Share Offering	23-05-26	MT
Certain Warrants of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	23-05-15	CI
Certain Common Stock of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	23-05-15	CI
Certain Options of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	23-05-15	CI
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected	23-05-12	MT
US Futures Trend Higher Ahead of Import/Export Data, Consumer Sentiment Survey Results	23-05-12	MT
Top Premarket Gainers	23-05-12	MT
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Weak Corporate Earnings Weigh on Sentiment, Fueling Premarket Losses for US Equity Futures	23-04-20	MT
Top Premarket Gainers	23-04-20	MT
Top Premarket Gainers	23-04-18	MT

Chart Dermata Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Sector

Biotechnology & Medical Research

Calendar

2024-09-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.63 USD

Average target price

10 USD

Spread / Average Target

+280.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DERMATA THERAPEUTICS, INC.	-71.26%	1.48M
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	115B
ARGENX SE	+22.18%	26.64B
BIONTECH SE	-21.81%	19.91B
GENMAB A/S	-16.89%	16.32B
BEIGENE, LTD.	-18.81%	15.49B
WUXI APPTEC CO., LTD.	-44.74%	15.52B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.67B

Bio Therapeutic Drugs